[Therapeutic perspectives in multiple sclerosis].
Although consistent progress has been made over the last decade in the treatment of the inflammatory component of multiple sclerosis, these strategies have only partial efficacy. Numerous innovative therapeutic perspectives are emerging: currently, monoclonal antibody induced inhibition of entry of activated lymphocytes into the central nervous system is promising, but the benefit/risk ratio has still to be evaluated. In parallel, combination strategies with immunomodulators and/or immunosuppressants, and specific immunotherapy are investigated. In addition, in the longer-term, there is active development of experimental strategies aimed at repairing damaged tissue--both axon and myelin. These strategies are still at the preclinical stage. Therapeutic optimisation may come from an association between anti-inflammatory treatments acting upstream on the immune response, and neuroprotective and myelin repair strategies acting downstream, directed at the lesions.
Lubetzki
Catherine
C
Fédération des maladies du système nerveux, hopital La Salpêtrière, AP-HP, université Pierre et Marie Curie, 75651 Paris 13. catherine.lubetzki@psl.aphp.fr
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D009103:Multiple Sclerosis / Q000628:therapy*; D009186:Myelin Sheath / Q000187:drug effects / Q000502:physiology; D000069442:Natalizumab; D033581:Stem Cell Transplantation
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab